American Journal of Psychiatry Submission Guide

AJP's Information for Contributors calls its primary research-article format simply Articles (this page says Regular Article) and states these limits:

Source: AJP Information for Contributors, accessed April 2026.

The 3,500-word Regular Article cap is significantly tighter than NEJM's flexible structure, JAMA Psychiatry's typical 4,000-word Original Investigation, or Lancet Psychiatry's typical 3,500-4,500 word Articles. Word count includes only main body text. Abstract, tables, figures, references, and online supplements are excluded.

The 5-table-and-figure ceiling is the constraint authors most commonly miss. A trial paper with primary outcome figures, subgroup analyses, demographics tables, and adverse event tables can easily exceed 5 displays. The fix is to consolidate or move secondary analyses to an online supplement.

Verify the current Editor-in-Chief on the journal's editorial-team page before quoting any name in a cover letter. The Editor-in-Chief and the Deputy Editors conduct an initial review of every submission to determine "originality, validity, and importance of content and conclusions." Manuscripts with insufficient priority for publication are rejected promptly without external review.

The practical consequence: AJP's desk screen is editorial-priority focused, not just scope-fit focused. The question is not "is this psychiatry?" but "is this AJP-priority psychiatry?" Recent editorial priorities reflect the journal's traditional strengths in psychopharmacology, schizophrenia treatment, and clinical trials, alongside primate models of anxiety and depression, pediatric psychiatry, and translational neuroscience.

The cover letter has higher weight at AJP than at journals with category-based editorial routing (like Management Science's department system). Use it to explain why the work meets the AJP priority bar, not just to summarize the abstract.

Disclose any generative-AI use in both places

The current AJP Information for Contributors

requires authors who used a generative-AI tool at any stage of a submitted work

to fully identify that use in both the relevant manuscript text and the

accompanying letter or email. Identify the tool and the relevant output rather

than relying on a vague statement that AI was used.

This is separate from the clinical-priority case. A clean letter first states

what the study changes for clinical psychiatry, then makes any required AI-use

disclosure easy for the editor to find. Do not claim authorship for an AI tool:

the authors remain responsible for the submitted work.

AJP doesn't publish formal desk-rejection statistics. The unofficial 12% acceptance-rate estimate combined with the editorial-priority screen suggests a substantial fraction of submissions are rejected before peer review. Three operational signals govern editorial review:

1. Clinical relevance is concrete, not theoretical. AJP is a clinical journal at its core. Papers whose findings could change practicing-psychiatrist behavior or psychiatric clinical guidelines fare better than papers whose contribution is primarily mechanistic or theoretical. A psychedelic-assisted therapy trial with a clear treatment-protocol implication; a pharmacogenomic finding that affects prescribing decisions; a neuroimaging biomarker with documented clinical utility. These match the AJP priority signal. Pure-mechanism papers without proximate clinical relevance often fit Biological Psychiatry, Molecular Psychiatry, or Translational Psychiatry better.

2. Priority for the AJP audience is broad-clinical, not narrow-subspecialty. AJP's readership spans clinical psychiatrists, psychiatric researchers, and policy stakeholders. Papers that matter to a single sub-specialty (forensic psychiatry, geriatric psychiatry, addiction medicine, etc.) face higher editorial-priority scrutiny than papers whose results inform clinical psychiatry broadly. The fix is to articulate broader-clinical relevance honestly, or route the paper to a sub-specialty journal where the contribution lands more naturally.

3. Methodological rigor meets AJP's standard for clinical trials and observational studies. AJP's instructions require a CONSORT-format flow diagram and the CONSORT checklist information for randomized clinical trials, and registration of clinical trials in a public registry. STROBE and PRISMA are the usual reporting standards for observational studies and reviews. Papers with thin reporting against these standards need a stronger editorial package regardless of substantive interest. Pre-registration, protocol publication, and conflict-of-interest disclosure matter at AJP as much as at JAMA Psychiatry and Lancet Psychiatry.

Recent papers in AJP, with DOIs:

• "Psychological Support for Investigational Psilocybin Treatment" (December 2024), 10.1176/appi.ajp.20230884. Framework paper on psychological support during investigational psilocybin trials, reflecting AJP's active engagement with psychedelic-assisted therapeutics.

• "Treatment Approaches" by Aaron S. Wolfgang, Vetisha L. McClair, Paula P. Schnurr et al. (January 2025), 10.1176/appi.ajp.20240751. Recent treatment-approaches paper.

• "2023 Articles of Import and Impact" (2024 retrospective summary), 10.1176/appi.ajp.24181001. AJP's annual retrospective on the previous year's most-cited and most-impactful papers. a useful signal for understanding what the journal considers its strongest work.

The pattern across AJP papers: clinical relevance is the connective thread. Whether the topic is psychedelic-assisted therapy, pharmacogenomics, brain imaging in schizophrenia, or treatment of treatment-resistant depression, the through-line is research that informs psychiatric clinical practice within a 5-year horizon, not 20-year basic science.

Before submitting to American Journal of Psychiatry, an American Journal of Psychiatry manuscript fit check identifies whether the package meets the editorial bar before you commit to the submission.

This is the AJP-specific submission detail authors most often miss:

APA Publishing does not accept article processing charges to make the official published version of an AJP article freely available upon publication as Open Access.

That is, AJP does not offer a standard hybrid OA model. There is no APC option. The official version becomes freely available to the public on the journal's website 12 months after publication.

For most authors this isn't a constraint. APA's institutional subscriptions are widespread. But authors with NIH OA mandates (Public Access Policy), Wellcome OA requirements, or other funder OA mandates need to verify whether AJP's repository deposit pathway satisfies the mandate before submission. At submission, authors choose one of three access-policy options: NIH-funded work, for which APA Publishing submits the accepted manuscript to the NIH Manuscript Submission system on the author's behalf; funder-mandated deposit of the accepted manuscript under a CC BY 4.0 license after an embargo of 0 days to 12 months agreed by all parties; or no stipulations, in which case the official version is free to the public 12 months after publication.

The strategic implication: if you have a strict OA mandate that requires the official published version (not a green-OA preprint deposit) to be freely available immediately, JAMA Psychiatry, Lancet Psychiatry, BJPsych, or Biological Psychiatry may be a more compatible target than AJP.

For the initial submission via Manuscript Central:

1. Title page with all author names, affiliations, and corresponding author contact

1. The manuscript with main text usually within 3,500 words, abstract of no more than 250 words, up to 5 tables and figures combined, up to 40 references

1. Cover letter explaining why the work meets the AJP priority bar

1. Suggested reviewers (required)

1. Conflict-of-interest disclosure for all authors

1. Reporting checklist appropriate to study type (the instructions require a CONSORT flow diagram and checklist information for randomized trials)

1. Clinical-trial registration for trials in a public registry (registration information goes in the cover letter, and the registration at the end of the abstract)

1. Online supplement for supplemental data the instructions allow online (detailed tables, the CONSORT table and figure for trials, and appendices)

1. Authorship statement in the cover letter, alongside the disclosure and copyright-transfer statements

1. Funding statement disclosing NIH, foundation, or sponsor support

1. Ethics statement with IRB approval and informed-consent process for human-subjects research

1. Participant-data answers in the submission system for studies of human participants (how race, ethnicity, sex and gender were ascertained, IRB approval, written informed consent, and trial registration)

A American Journal of Psychiatry submission readiness check before upload can flag whether the manuscript fits the 3,500-word format cleanly, whether the 5-display ceiling is respected, whether the cover letter makes the AJP priority case, and whether the funder's OA mandate is compatible with APA's subscription model.

AJP's flow follows the APA Publishing process. The stage timings below are unofficial planning estimates, not timings published by AJP or APA Publishing.

• Day 0: Manuscript Central upload. The ScholarOne submission portal portal accepts the package and routes to the Editor-in-Chief and Deputy Editors for editorial review.

• Days 1 to 21: Editorial review. EIC and Deputies assess priority for publication; the 1 to 3 week editorial review concentrates here.

• Days 21 to 28: Initial decision. Many submissions are returned at this stage as desk rejection without external review.

• Days 28 to 96: Peer review. Reviewer reports return during this window.

• Days 96 to 120: First editorial decision. Major revision is the most common positive outcome.

• Days 120 to 240: Revision rounds and acceptance. Single-revision acceptances run roughly 5 to 7 months; multi-round revisions push closer to 9 months. Publication queue adds another 1 to 3 months.

Across psychiatry manuscripts targeting American Journal of Psychiatry, three decision risks matter most before peer review: format compliance, visible clinical relevance, and open-access mandate fit.

AJP's published contributor instructions state the manuscript limits: usually within 3,500 words of main text, an abstract of no more than 250 words, 5 tables and figures in total, and up to 40 references. Its editorial-priority screen asks whether the work could plausibly change psychiatric clinical practice or guidelines within a reasonable time horizon. Its open-access model is unusual among nearby psychiatry flagships because there is no standard hybrid APC route for the official published version.

Use the three checks below before you open the submission portal.

Format-limit risk

Across AJP-targeted manuscripts, we consistently see authors arriving from journals with looser word caps and submitting papers that violate the AJP Regular Article format.

AJP's instructions give 3,500 words as the usual limit for main text, so check the current Information for Contributors before upload.

Specific patterns editors flag:

• main-text word count of 4,000-6,000 when the Regular Article cap is 3,500 words

• authors counting the abstract, tables, figures, references, or supplement against the wrong word-count bucket

• 300-350 word abstracts when 250 words is the cap

• 6-8 tables and figures when 5 combined is the cap

• 60-100 references when 40 is the cap

The fix is mechanical: count main-body words against the 3,500-word ceiling, count tables and figures together against the 5-display ceiling, tighten the abstract to 250 words, and move overflow material to the online supplement. If the paper cannot fit the Regular Article format naturally, choose the article type whose limits actually match the manuscript.

Check whether your AJP manuscript fits the Regular Article format before upload ->

Clinical relevance buried too late

We frequently see AJP manuscripts bury clinical-implication statements in the discussion section while the abstract and introduction present methodological / statistical / mechanistic framing without immediate clinical-practice-changing argument.

AJP editors and Deputy Editors decide priority within minutes of receiving a submission, and the priority screen turns on whether the work could plausibly change clinical psychiatric practice or psychiatric clinical guidelines within 5 years.

The clinical-implication argument has to be visible in the first 2-3 paragraphs of the introduction and the abstract's Conclusions section.

Specific patterns AJP editors flag:

• an abstract conclusion that says "implications for future research" without naming the clinical decision the work informs

• an introduction that motivates the work through a methods gap but does not name the clinical question

• results that emphasize p-values without translating them into clinically meaningful magnitude

• a cover letter that argues novelty or rigor without naming the clinical-practice change

AJP's priority screen specifically checks for a named clinical decision, a named patient population, a comparison with the current standard of care, and a realistic sense of how close the result is to practice change.

Manuscripts where clinical implications are not visible in the first 2-3 paragraphs face desk rejection regardless of methodological strength.

The fix is to write the introduction so the first paragraph names the clinical-decision tension, the second paragraph names the population and current-standard limitation, and the third paragraph states what the present work changes for clinical practice. The abstract conclusion and cover letter should make the same case in shorter form.

Check whether your AJP abstract makes the clinical-priority case immediately ->

Open-access mandate risk

The third recurring pattern in AJP-targeted manuscripts is authors with strict NIH, Wellcome, UKRI, ERC, NHMRC, CIHR, or other funder OA mandates submitting to AJP, being accepted, and then discovering at production stage that AJP's publication model does not satisfy the funder mandate.

AJP is the rare top-5 clinical psychiatry flagship that does not offer a standard hybrid open-access APC option (unlike JAMA Psychiatry's CC BY option, Lancet Psychiatry's hybrid OA, Molecular Psychiatry's hybrid OA, Biological Psychiatry's hybrid OA, Translational Psychiatry's full OA, World Psychiatry's free access).

APA's open-access posture for AJP is different from the nearby hybrid-OA journals authors often compare it with:

• subscription publication is the default

• there is no ordinary APC path for making the official published version open on publication

• the official version becomes free to the public 12 months after publication

• repository deposit and embargo rules need to be checked against the author's funder mandate

Specific patterns we see include multi-funder collaborations with conflicting OA requirements, institutional Read-and-Publish coverage assumed but not verified, and authors discovering mandate issues only after acceptance.

The fix is to verify OA-mandate compatibility before submission. Check the funder policy, ask the institutional library whether AJP is covered by a Read-and-Publish agreement, and identify alternative venues if the official published version must be immediately open under a specific license.

Check whether your AJP manuscript is submission-ready ->

• American Journal of Psychiatry under review

• Is the American Journal of Psychiatry a good journal?

• JAMA Psychiatry Submission Guide

• Lancet Psychiatry Submission Guide

We reviewed the AJP Information for Contributors, the APA Publishing Access Policy, the AJP journal home, and recent issues for landmark papers. We see consistent patterns in Manusights submission reviews that match what the AJP materials describe.

In our pre-submission review work for AJP submissions, the stronger drafts made the clinical decision, patient population, 3,500-word Regular Article structure, 250-word abstract, display budget, reporting checklist, trial registration, and open-access mandate check visible before the editor had to infer clinical priority from the discussion.

Source limitations: AJP and APA official guidance explains contributor requirements, format limits, submission mechanics, and open-access policy, but it does not publish manuscript-level desk decisions. The patterns below combine official guidance with anonymized Manusights pre-submission review work and public issue patterns.

Our analysis of recent AJP issues focused on whether accepted Regular Articles make the patient population, clinical decision, guideline relevance, trial or cohort design, display logic, and practice implication visible before the reader reaches the discussion.

The official checklist explains what to upload. The practical AJP screen is whether the manuscript can tell a clinical psychiatrist what decision could change within a reasonable time horizon. The review tells you whether the paper makes that clinical-priority case before the format constraints and OA policy become expensive surprises.

• American Journal of Psychiatry Under Review status

Desk screening is a fit test first and a compliance test second. Match my abstract against American Journal of Psychiatry before I reformat and its neighbours.

Last verified: June 30, 2026 against the AJP Information for Contributors page, the APA Publishing Open Access page, current JIF disclosures, and recent issues of the journal.